J. Ellerton

发表

Phase II study of continuous-infusion diaziquone in relapsed/refractory acute nonlymphocytic leukemia.

P. Schulman, R. Davis, E. Lee, 1987, Cancer treatment reports.

Phase II Study of Intravenous CI-958 in Metastatic Colorectal Adenocarcinoma

R. Winn, R. Pazdur, S. Dakhil, 2000, American journal of clinical oncology.

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.

L. Norton, W. Wood, I. Henderson, 1994, The New England journal of medicine.

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

R. Larson, B. Peterson, L. Silverman, 2005 .

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

J. Holland, R. Larson, R. Stone, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.

J. Herndon, D. Hollis, M. Green, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

A. Ravaud, L. Dirix, C. Britten, 2018, The Lancet. Oncology.

Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer

S. Gettinger, X. Pan, G. Otterson, 2010, Clinical Cancer Research.

Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

J. Herndon, M. Green, G. Clamon, 1993, Journal of the National Cancer Institute.

Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study

J. Herndon, M. Green, S. Graziano, 2004, Cancer Chemotherapy and Pharmacology.

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

A. Ravaud, L. Dirix, J. Infante, 2020, Journal for ImmunoTherapy of Cancer.

Randomized Control led Tria l o f Azac i t id ine in Pat ients With the Myelodysplas t ic Syndrome : A Study of the Cancer and Leukemia Group B

J. Holland, R. Larson, R. Stone, 2017 .

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

J. Holland, R. Larson, C. Decastro, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

R. Marks, K. Kelly, J. Herndon, 2005, Journal of Clinical Oncology.

A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.

C. Bloomfield, B. Peterson, B. Poiesz, 1992, Journal of immunotherapy.

Dose-Response T rial o f M egestrol A cetate i n A dvanced Breast C ancer: C ancer a nd L eukemia G roup B Phase I II S tudy 8 741

D. Berry, L. Norton, J. Abrams, 1999 .

Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.

D. Berry, L. Norton, J. Abrams, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.

C. Schiffer, K. Dear, C. Schiffer, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group.

C. Begg, J. Cohen, J. Ellerton, 1980, Cancer clinical trials.

Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).

J. Tepper, R. Goldberg, D. Niedzwiecki, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of echinomycin in patients with advanced breast cancer: A report of cancer and leukemia group B protocol 8641

R. Schilsky, D. Faraggi, W. Wood, 1991, Investigational New Drugs.

Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.

A. Ravaud, L. Dirix, C. Britten, 2017 .

Erythroleukemia in a renal transplant recipient

M. Baker, J. Ellerton, G. Deveber, 1979, Cancer.

Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial.

A. Ravaud, L. Dirix, C. Britten, 2017 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible

L. Dirix, M. Schlichting, J. Infante, 2016 .

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.

M. Michaelson, A. Zietman, H. Sandler, 2023, European urology oncology.

Results of a phase I study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer

J. Schiller, G. Otterson, M. Villalona-Calero, 2005 .

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.